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Abstract
Background: BMI-1 is a member of the polycomb group of genes (PcGs), and it has been implicated in the development
and progression of several malignancies, but its role in osteosarcoma remains to be elucidated.
Methodology/Principal Findings: In the present study, we found that BMI-1 was overexpressed in different types of
osteosarcomas. Downregulation of BMI-1 by lentivirus mediated RNA interference (RNAi) significantly impaired cell viability
and colony formation in vitro and tumorigenesis in vivo of osteosarcoma cells. BMI-1 knockdown sensitized cells to cisplatin-
induced apoptosis through inhibition of PI3K/AKT pathway. Moreover, BMI-1-depletion-induced phenotype could be
rescued by forced expression of BMI-1 wobble mutant which is resistant to inhibition by the small interfering RNA (siRNA).
Conclusions/Significance: These findings suggest a crucial role for BMI-1 in osteosarcoma pathogenesis.
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Introduction
Primary osteosarcoma is the most common bone tumor that
predominantly develops in adolescents and young adults [1]. Even
after the introduction of aggressive chemotherapy and wide
excision of tumors, 30–50% of patients with initially localized
disease subsequently developed recurrence, which has an ex-
tremely poor clinical outcome. Moreover, 20–30% of newly
diagnosed cases presented with metastatic disease [2,3]. Therefore,
identifying the effector molecules and/or signal transduction
pathways that regulate the carcinogenesis and malignant devel-
opment is crucial for understanding the vulnerabilities of
osteosarcoma and for isolating molecular targets that may disrupt
the tumor machinery whereas protecting the integrity and function
of normal tissue.
BMI-1 is a member of the polycomb group family of
transcriptional regulators that was originally identified as an
oncogenic partner of c-Myc in murine lymphomagenesis [4].
BMI-1 is essential for blood-cell development and the self-renewal
capacity of several types of normal and cancer stem cells [5], and it
is also important for cell cycle regulation, since both p16/INK4a
and p14/ARF are downstream targets of BMI-1 [6,7]. Experi-
mental studies convincingly link BMI-1 to carcinogenesis, for
instance, aberrant expression of BMI-1 has been associated with
malignant tumors of the hematopoietic and lymphatic systems
[8,9], melanoma [10], neuroblastoma [11], endometrial carcino-
ma [12], non-small cell lung cancer [13] and breast cancer [14].
Further more, high expression of BMI-1 in a panel of epithelial
cancers including nasopharyngeal was associated with poor patient
outcome [15,16]. Molecular investigations have suggested a role
for BMI-1 by immortalization of mammary epithelial cells through
induction of telomerase activity and regulation of cancer cells with
stem-cell like properties [17,18]. Overexpression of BMI-1
downregulates expression of p16INK4a and p14ARF, allows
fibroblast immortalization, and in combination with H-ras leads to
neoplastic transformation [14].
Although BMI-1 has been implicated as an oncogenic player,
very little is known about the exact function of BMI-1 in
osteosarcoma growth and progression. In this study we have
investigated whether BMI-1 functions as an oncogene in
osteosarcoma. Our findings confirm that BMI-1 is highly
expressed in osteosarcoma cells, and it promotes tumor growth
in vitro and in vivo. Furthermore, our data show that BMI-1 also
play an important role in osteosarcoma cell migration and
chemosensitivity to cisplatin-induced apoptosis.
Results
Overexpression of BMI-1 in osteosarcoma
As elevated BMI-1 expression was found in several types of
human cancers, we first determine the expression of BMI-1
protein in osteosarcoma through immunohistochemical analysis.
BMI-1 expression was not detected in 10 patients with
noncancerous bone tissues. In contrast, positive expression of
BMI-1 was observed 18/32 in osteosarcoma, 9/22 in chondro-
sarcoma, 3/9 in Ewing’s sarcoma and 5/27 in osteochondroma (a
benign neoplasm) (Figure 1). These data indicated that BMI-1 is
ubiquitously upregulated in some types of osteosarcoma. Statistical
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malignant bone tumors was significantly different, but elevated
expression of BMI-1 was not correlated with any clinicopathologic
parameters in the available 90 specimens.
BMI-1 knockdown inhibits osteosarcoma cell growth
both in vitro and in vivo
To suppress BMI-1 expression in osteosarcoma cells, short
harpin RNA (shRNA) targeting BMI-1 gene was designed and
inserted into the recombinant lentivirus plasmid. To verify that the
effects of RNA interference (RNAi) are specific, we prepared a
BMI-1 construct bearing triple-point mutation in the 19-bp
sequence that served as target for small interfering RNA
(siRNA)-mediated knockdown. The mutation conserved the amino
acid sequence of the BMI-1 protein but rendered its expression
insensitive to inhibition by the siRNA. Effeciency of lentivirus
infection was more than 90% as evidenced by GFP expression 3
days after infection (Figure 2A). BMI-1 mRNA expression was
Figure 1. Immunohistochemical staining of BMI-1. BMI-1 immunoreactivity was localized in both the nucleus and cytoplasm. Images of
positive BMI-1 staining in nucleus of osteosarcoma, osteochondroma and chondrosarcoma, and in cytoplasm of Ewing’s sarcoma were shown (6400).
Negative BMI-1 staining in a non-cancerous tissue sample served as control.
doi:10.1371/journal.pone.0014648.g001
Figure 2. Targeted depletion of BMI-1 through lentivirus-mediated siRNA. (A) Representetive graphs of SAOS-2 cells infected with indicated
lentivirus at MOI of 10 were shown (6400). Following infection of cells with indicated lentivirus for 5 days, BMI-1 mRNA levels were measured with
real-time PCR (B), and protein levels were detected by Western blot analysis (C). *: P,0.01, compared to control cells. Con: non-infected, NC: non-
silencing, KD: BMI-1 knock down, Rescue: BMI-1 wobble mutant.
doi:10.1371/journal.pone.0014648.g002
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endogenous BMI-1 mRNA was obviously reduced in BMI-1
knockdown group. We further determined the suppression effect
by measuring BMI-1 protein levels using immunoblot. It was
demonstrated that BMI-1 protein level was significantly downreg-
ulated following BMI-1 knockdown treatment (Figure 2C).
To elucidate the role of BMI-1 in osteosarcoma proliferation
and tumorigenesis, the growth of each lentivirus infected SAOS-2
cells were first examined by MTT assay. Figure 3A showed that
the growth curves for BMI-1 knockdown cells were significantly
lower than those for control cells and BMI-1 rescued cells for 4
days of incubation. Furthermore, colony formation assay in
monolayer culture showed that the number of surviving colonies
of BMI-1 knockdown cells was markedly decreased compared to
those of control cells, suggesting that BMI-1 expression is
detrimental to the colony formation of osteosarcoma cells
(Figure 3B). Next, in vivo subcutaneous tumor formative assay
was adopted to examine the tumorigenesis of SAOS-2 cells in
nude mice. Compared to control cells expressing non-silencing
small interfering RNA (siRNA), the injection of BMI-1 knockdown
cells led to a significantly decrease in tumor volume and size.
Conversely, BMI-1 rescued cells partially restored the proliferative
ability in nude mice (Figure 3C). Both in vitro and in vivo assays
suggested that BMI-1 had the potential to inhibit proliferation,
colony formaton, and tumorigenicity of osteosarcoma.
Downregulation of BMI-1 inhibits osteosarcoma cell
migration
We also examined the role of BMI-1 in osteosarcoma cell
migration. SAOS-2 cells treated with BMI-1 siRNA-expressing
lentivirus demonstrated decreased ability to migrate through 8-
mm-pore-size membranes that were not coated with Matrigel
Figure 3. Effects of BMI-1 siRNA on the in vitro proliferation, colony formation, and in vivo tumorigenicity of osteosarcoma cells. (A)
The monolayer growth rates of SAOS-2 cells from different groups were determined by MTT assay. (B) Downregulation of BMI-1 inhibited colony-
forming ability. Photographs of plates and representative colonies were shown. Histogram was the average number of colonies in each plate. (C)
Downregulation of BMI-1 reduced the tumorigenicity of SAOS-2 cells. The change of tumor volume during 5 weeks of inoculation was measured.
Representative pictures of tumor bearing mice and tumors were shown (n=10). Values represent the mean (standard error of the mean) from at least
three separate experiments. *: P,0.01, compared to control cells. Con: non-infected, NC: non-silencing, KD: BMI-1 knock down, Rescue: BMI-1 wobble
mutant.
doi:10.1371/journal.pone.0014648.g003
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further infected with the lentivirus encoding a BMI-1 wobble
mutant, cell migration was substantially rescued (P,0.05).
Knockdown of BMI-1 sensitized osteosarcoma cell to
cisplatin treatment
It has been reported that knockdown of BMI-1 makes
nasopharyngeal carcinoma cells more sensitive to 5-FU treatment
and that depletion of BMI-1 enhances 5-FU-induced apoptosis
[19]. These observations prompted us to investigate the possibility
of the combination of cisplatin treatment and BMI-1 depletion as a
clinical strategy for osteosarcoma chemotherapy. As shown in
Figure 5A, total percent of apoptotic BMI-1 knockdown cells (cells
in early and late apoptosis) was about double that of the control
and parental cells in the assessment by Annexin V-FITC/PI
(propidium iodide) staining. However, the addition of cisplatin
significantly increased apoptosis in BMI-1 knockdown cells,
suggesting that combining BMI-1 inhibition with cisplatin
enhanced the incidence of apoptosis.
We subsequently explore the possible molecular mechanism by
which BMI-1 protected osteosarcoma cells from cisplatin induced
apoptosis. Caspases are important regulators of apoptosis.
Therefore, the involvement of caspase-3 and caspase-9 in
cisplatin-induced apoptosis was investigated. In the BMI-1
knockdown cells, after treatment with cisplatin (10 mg/ml),
caspase-3 and caspase-9 activities were observed to be increased
by 2.4-fold and 2.7-fold, respectively (Figure 5B).
Further more, expression levels of total-AKT, phospho-AKT (p-
AKT), Bid and BCL-2 were examined in BMI-1 knockdown cells,
BMI-1 rescued cells and control cells. Immunoblot analysis
showed that the knockdown of endogenous BMI-1 led to
significant reduction in the levels of phospho-AKT and BCL-2,
whereas pro-apoptotic protein Bid was elevated in BMI-1
knockdown cells. Nevertheless, wobble mutant of BMI-1 rescued
the expression of phospho-AKT, BCL-2 and Bid protein in
SAOS-2 knockdown cells (Figure 5C).
Discussion
In the present study, we found that BMI-1 was highly expressed
in malignant osteosarcoma, and it is essential for cancer cell
proliferation, migration and in vivo tumorigenicity. We demon-
strated for the first time that the knockdown of endogenous BMI-1
expression contributed to sensitizing osteosarcoma cells to the
anticancer drug cisplatin by increasing apoptosis.
Recently, it is reported that osteosarcoma might originate from
somatic stem cells [20]. Given that BMI-1 is upregulated in most
stem cells and its expression is vital for the self-renewal of normal
and tumorigenic stem cells [21], it is possible that the high level of
BMI-1 expression we observed in osteosarcoma cells is an inherent
feature of their cellular origin. Recently, Douglas et al. also found
that BMI-1 is highly expressed in Ewing sarcoma family of tumors
and that it regulates sarcoma cell adhesion and growth in nude
mice [22]. In addition their expression profiling studies following
BMI-1 knockdown revealed that part of downstream target genes
of BMI-1 were involved in cell-cell and cell-matrix adhesion.
However, they observed that BMI-1 does not significantly affect
proliferation or survival, suggesting that this property of BMI-1 is
limited to certain type of osteosarcoma cells.
Due to the therapeutic advantages, such as high efficiency, mild side
effects and easy administration, cisplatin is still one of the most
common used agents in chemotherapy. However, resistance to this
drug is also often observed, and therefore enhancing the sensitization of
cancer cells to cisplatin-induced apoptosis has become an important
strategy for chemotherapy. We found that the depletion of BMI-1 in
SAOS-2 cells, in which BMI-1 is highly expressed, resulted in an
increased sensitivity of these cells to cisplatin. Pro-caspase-3, an effector
caspase of apoptosis, is one of the effector pro-caspases activated by
caspase-9 [23]. Measurement of caspase-3 and caspase-9 activities
further confirmed that silencing BMI-1 expression could enhance
cisplatin-induced apoptosis, further explaining clearly the signaling
pathway of cisplatin-induced apoptosis in osteosarcoma.
It is well known that p53 induces apoptosis in response to DNA
damage, and SAOS-2 cells have a wild-type p53. Therefore we
hypothized that p53 might be responsible for increased apoptosis
after cisplatin treatment in BMI-1 knockdown cells. However,
mRNA and protein levels of p53 and its effecter p21 were
downregulated upon BMI-1 knockdown (data not shown). We
assumed that the apoptosis in the SAOS-2 cells reported herein
was p53-independent. Activation of the PI3K/AKT pathway
enhances resistance to apoptosis is observed in a wide variety of
cancers [24,25]. In the present study, inhibition of the PI3K/AKT
pathway after BMI-1 knockdown was found to play a role in the
sensitivity of SAOS-2 cells to cispatin treatment. The ratio of the
anti-apoptotic to pro-apoptotic proteins is important in determin-
ing cell apoptosis and survival after DNA damage. We also found
decreased BCL-2 levels and Bid accumulation in BMI-1
knockdown cells, and BCL-2 and Bid levels were attractively
rescued with overexpression of BMI-1, indicating that BMI-1
could regulate the ratio of BCL-2 to Bid in SAOS-2 cells.
In summary, our results demonstrated that BMI-1 functions as an
oncogene in osteosarcoma and that it promotes tumorigenicity and
resistance to chemotherapy. Our findings suggest that the combination
Figure 4. Downregulation of BMI-1 suppresses osteosarcoma
cell migration. (A) Statistical plots of haptotactic migration assay.
Columns, mean of three individual experiments; bars, SD;*: P,0.01,
compared to indicated cells. (B) Representative photos of haptotactic
migration assay. Con: non-infected, NC: non-silencing, KD: BMI-1 knock
down, Rescue: BMI-1 wobble mutant.
doi:10.1371/journal.pone.0014648.g004
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strategy for osteosarcoma.
Materials and Methods
Tissue specimens
Ninety patients who were histologically confirmed as having
osteosarcoma, chondrosarcoma, Ewing sarcoma, osteochondroma,
and normal bone tissues were enrolled Peking Union Medical College
Hospital, China. The clinicopathologic variables such as gender, age,
the histologic type and the status of the resection margin were
retrospectively reviewed on the basis of the medical records. All
patients received no treatment befo r es u r g e r y .T h es a m p l e sw e r eu s e d
with the written informed consent from patient and the approval of the
ethic committee of Peking Union Medical College Hospital, China.
Cell culture
Human embryonic kidney 293T (HEK293T) cell line and the
osteosarcoma cell line (SAOS-2) were obtained from the American
Type Culture Collection (ATCC, Rockville, MD, USA). Cells
were cultured in Dulbecco’s modified Eagle’s medium (Gibco RL,
Grand Island, NY, USA) supplemented with 10% fetal bovine
serum, 100 U/ml penicillin, and 100 mg/ml streptomycin.
Construction of recombinant Lentivirus and gene
silencing
The siRNA sequence for BMI-1 (59-CAGATTGGATCG-
GAAAGTA-39) was selected after screening to validate potential
siRNAs. Non-silencing siRNA (59-TTCTCCGAACGTGT-
CACGT-39) was used as control. ShRNAs, corresponding to
siRNA sequences for BMI-1 and non-silencing, were then
generated, respectively. These were synthesized as a 21-nt inverse
repeat separated by a 9-nt loop for each sequence and inserted
downstream of the U6 promoter in the lentiviral vector pGCL-
GFP (GeneChem Co., Ltd., Shanghai, China). Lentiviruses were
generated by triple transfection of 80% confluent HEK293T cells
with modified pGCL-GFP plasmid and pHelper 1.0 and pHelper
2.0 helper plasmids (GeneChem Co., Ltd., Shanghai, China) using
Lipofectamine 2000 (Invitrogen, Carlsbad, CA, USA). Lentivirus-
es were harvested in serum-free medium after 3 days, filtered and
concentrated in primed Centricon Plus-20 filter devices (Millipore,
Billerica, MA, USA). BMI-1 wobble mutant preserving the same
amino acid sequence, but containing triple-point mutations in the
target nucleotide sequence and therefore resistant to BMI-1
siRNA, was produced by GeneChem Co., Ltd. (Shanghai, China).
RNA extraction and real-time PCR
Total RNA was prepared using Trizol reagent (Gibco RL,
Grand Island, NY, USA) according to the manufacturer’s
instruction. Five mg of total RNA was used to synthesize the first
strand of cDNA using SuperScript II RT 200 U/ml (Invitrogen,
Carlsbad, CA, USA). BMI-1 mRNA expression was evaluated by
real-time PCR on an ABI PrismH 7300 (Applied Biosystems,
Foster City, CA, USA) with SYBR Green PCR core reagents. b-
actin was applied as the input reference. The following primers
were used: BMI-1: 59-TGGCTCGCATTCATTTTCTG-39 as
Figure 5. BMI-1 depletion sensitized cells to cisplatin treatment through PI3K/AKT pathway. After infection, SAOS-2 cells were treated
with 10 mg/ml cisplatin for 24 h and subjected to Annexin V-PI Apoptosis analysis (A) and measurement of caspase-3 and caspase-9 activities (B). (C)
Western blot analysis of p-AKT, AKT, BCL-2 and Bid protein. *: P,0.01, compared to control cells. Con: non-infected, NC: non-silencing, KD: BMI-1
knock down, Rescue: BMI-1 wobble mutant, Annexin V
2/PI
2: viable cells, Annexin V
+/PI
2: cells in early apoptosis, Annexin V
+/PI
+: cells in late
apoptosis, Annexin V
2/PI
+: cells in necrosis.
doi:10.1371/journal.pone.0014648.g005
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b-actin: 59-GGCGGCACCACCATGTACCCT-39 as forward
and 59-AGGGGCCGGACTCGTCATACT-39 as reverse. Re-
sults are presented as CT values, defined as the threshold PCR
cycle number at which an amplified product is first detected. The
average CT was calculated for both BMI-1 and b-actin, and DCT
was determined as the mean of the triplicate CT values for BMI-1
minus the mean of the triplicate CT values for b-actin.
Immunohistochemical staining
The slides were deparafinized, rehydrated, then immersed in 3%
hydrogen peroxide solution for 10 min, heated in citrate buffer,
pH 6.0, at 95uC for 25 min, cooled at room temperature for 60 min.
The slides were blocked by 10% normal goat serum at 37uCf o r
30 min, and then incubated with rabbit polyclonal antibody against
BMI-1(1: 200, ProteinTech Group, Chicago, IL, USA) for overnight
at 4uC. After washing with PBS, the slides were incubated with
biotionylated second antibody (diluted 1: 100) for 30 min at 37uC,
followed by streptavidin-peroxidase (1: 100 dilution) incubation at
37uC for 30 min. Immunolabeling was visualized with a mixture of
DAB solution. Counterstaining was carried out with hematoxylin.
Samples were scored positive when more than 10% of the cells reacted
with the anti-BMI-1 antibody and presented cytoplasm staining.
Western blot analysis
Proteins were separated by SDS–PAGE, transferred to poly-
vinylidene difluoride (PVDF) membranes (Millipore, Bedford, MA,
USA). Blots were blocked and then probed with antibodies against
BMI-1(1: 500 dilution; Santa Cruz Biotechnology, Santa Cruz, CA,
USA), AKT (1: 1000 dilution; Santa Cruz Biotechnology, Santa
Cruz, CA, USA), phospho-AKT (Ser473; 1: 400 dilution; Santa
Cruz Biotechnology, Santa Cruz, CA, USA), Bcl-2 (1: 500 dilution;
Cell Signaling Technology Inc., Beverly, Massachusetts, USA), Bid
(1: 500 dilution; Cell Signaling Technology Inc., Beverly,
Massachusetts, USA), Mouse anti-GAPDH, (1: 5000 dilution;
Santa Cruz Biotechnology, Santa Cruz, CA, USA). After washing,
the blots were incubated with horseradish peroxidase-conjugated
secondary antibodies and visualized by super ECL detection
reagent (Applygen, Beijing, China).
Cell survival analysis
Briefly, cells from different groups were seeded at an initial
density of 5610
4 cells/ml in 96-well plates for 24 h. 3-(4, 5-
Dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide (MTT)
was added into each well at a final concentration of 5 mg/ml for
4 h. DMSO was then added to stop the reaction and measured
with an ELISA reader (Bio-Rad, Hercules, CA, USA) at a
wavelength of 570 nm. Viability of cells was expressed relative to
theoretical absorbance (A).
Colony formation assay and tumor formation in nude
mice
To assay monolayer colony formation, 200 infected cells were
plated in 6-well plates. After 2 weeks, cells were fixed with
methanol and stained with Giemsa. The number of colonies was
counted.
To assay tumor formation in nude mice, cloned pools of BMI-1
knockdown cells, scrambled RNAi cells, BMI-1 rescued cells, and
parental SAOS-2 cells were trypsinized, counted, and resuspended
in 16PBS. One hundred microlitre of 16PBS containing 10
6 cells
was then infected into 4-to 5-week-old female nude mice which
were purchased from Weitonglihua Company (Beijing, China).
The mice were examined for subcutaneous tumor growth and
sacrificed 5 weeks after injection. Animal study protocol was
reviewed and approved by the Institutional Animal Care and Use
Committee of Peking Union Medical College Hospital, China [the
permit number: SCXK (Jing) 2007-0001].
Migration assay
For haptotactic cell migration assay, 1610
4 cells from different
groups were seeded on a fibronectin-coated polycarbonate
membrane insert (6.5 mm in diameter with 8.0 mm pores) in a
transwell apparatus (Costar, Cambridge, MA, USA) and cultured
in DMEM. FBS was added to the lower chamber. After incubation
for 12 h at 37uCi naC O 2 incubator, the insert was washed with
PBS, and cells on the top surface of the insert were removed by
wiping with a cotton swab. Cells that migrated to the bottom
surface of the insert were fixed with methanol and stained by
Giemsa and then subjected to microscopic inspection. Cells were
counted based on five field digital images taken randomly at6200.
Flow cytometry assay
After lentivirus infection and cisplatin (10 mg/ml) treatment,
cells in each well were harvested and cell apoptosis was determined
by Annexin V-FITC/PI staining method. Tests were performed in
triplicate for each sample, and analyses were performed by FAC-
Scan flow cytometer (Becton Dickinson, San Jose, CA, USA) in
accordance with the manufacturer’s guidelines.
Measurement of caspase-3 and caspase-9 activities
The activation of caspase-3 and caspase-9 were determined in
SAOS-2 cells with the colorimetric kit (Nanjing kaiji Bio-Tek
Corporation, China). Cells (3610
6) were harvested and washed
twice with PBS.Afterthecells were lysed, 50 ml of2x reactionbuffer
was added followed by the additional 5 ml of caspase-3 or caspase-9
substrate and incubated at 37uC for 4 h. The plate was then read
with an ELISA reader (Bio-Rad, Hercules, CA, USA) at 405 nm.
Statistical analysis
All statistical analyses were performed using SPSS13.0 software.
The differences between groups were compared using Student’s t-
test, and data were expressed as mean 6 SD. Statistical difference
was accepted at P,0.05.
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